-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 17, the Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Seventh Batch of State-Organized Centralized Drug Purchasing Relevant Drug Information Reporting Work".
This national procurement involves a total of 58 varieties and 208 product specifications
.
The "Notice" requires that starting from February 18, the seventh batch of drug information reporting work related to centralized drug procurement organized by the state will be carried out
.
Industry insiders predict that the quotation time for the seventh batch of national mining will be from March 25 to April 10
.
This national procurement involves a total of 58 varieties and 208 product specifications
.
The "Notice" requires that starting from February 18, the seventh batch of drug information reporting work related to centralized drug procurement organized by the state will be carried out
.
Industry insiders predict that the quotation time for the seventh batch of national mining will be from March 25 to April 10
.
Four influencing factors
At present, the seventh batch of national procurement is still in the stage of quantity quotation, and no corresponding bid-winning rules have been issued.
Based on the centralized procurement rules for the first five batches of chemical drugs and the winning bids, the author believes that the factors affecting this quotation are:
Based on the centralized procurement rules for the first five batches of chemical drugs and the winning bids, the author believes that the factors affecting this quotation are:
1.
The number of competing products From the results of the first five batches of winning bids, the number of competing products is positively correlated with the price drop, that is, the more the number of competing products, the greater the drop
.
According to the previous bidding rules, when there are more than 6 shortlisted companies, at least 2 companies must be eliminated, of which there must be 1 generic drug company, so the competition is fierce, and there are 33 varieties that meet this condition
.
The number of competing products From the results of the first five batches of winning bids, the number of competing products is positively correlated with the price drop, that is, the more the number of competing products, the greater the drop
.
According to the previous bidding rules, when there are more than 6 shortlisted companies, at least 2 companies must be eliminated, of which there must be 1 generic drug company, so the competition is fierce, and there are 33 varieties that meet this condition
.
2.
With or without the centralized procurement of the first five batches of chemical drugs from the original research, a total of 260 billion yuan of drug costs have been saved
.
At the national level, it is proposed to continue to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
Judging from the previous centralized procurement experience and the patent cliff situation in Europe and the United States, about 10% of the original research enterprises may win the bid, in other words, 90% of the original research enterprises can achieve imitation substitution
.
According to statistics, 43 of the 58 varieties involve original research enterprises
.
With or without the centralized procurement of the first five batches of chemical drugs from the original research, a total of 260 billion yuan of drug costs have been saved
.
At the national level, it is proposed to continue to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
Judging from the previous centralized procurement experience and the patent cliff situation in Europe and the United States, about 10% of the original research enterprises may win the bid, in other words, 90% of the original research enterprises can achieve imitation substitution
.
According to statistics, 43 of the 58 varieties involve original research enterprises
.
3.
The centralized procurement of domestic leading enterprises is conducive to the realization of the centralization of the domestic generic drug industry
.
Judging from the number of over-reviews, domestic generic drug varieties are more and more concentrated in leading companies, and the stronger will inevitably become stronger in the future
.
The top domestic pharmaceutical companies have a high probability of winning the bid.
The reasons are as follows: First, corporate strategy.
Most of the domestic leading pharmaceutical companies have implemented the strategy of combining imitation and innovation and competition in the industry chain, and have already deployed the first generic drugs and APIs to achieve a one-year market exclusivity period.
The second is the advantage of product clusters.
The increase in the number of bid-winning products will reduce the marketing cost of unit varieties
.
Most of the domestic leading pharmaceutical companies have many successful bidders, and the resulting brand advantage can not only reduce the maintenance cost of the winning bidders, but also reduce the marketing cost of the non-bidding varieties, and realize the diminishing effect of marginal marketing costs
.
The centralized procurement of domestic leading enterprises is conducive to the realization of the centralization of the domestic generic drug industry
.
Judging from the number of over-reviews, domestic generic drug varieties are more and more concentrated in leading companies, and the stronger will inevitably become stronger in the future
.
The top domestic pharmaceutical companies have a high probability of winning the bid.
The reasons are as follows: First, corporate strategy.
Most of the domestic leading pharmaceutical companies have implemented the strategy of combining imitation and innovation and competition in the industry chain, and have already deployed the first generic drugs and APIs to achieve a one-year market exclusivity period.
The second is the advantage of product clusters.
The increase in the number of bid-winning products will reduce the marketing cost of unit varieties
.
Most of the domestic leading pharmaceutical companies have many successful bidders, and the resulting brand advantage can not only reduce the maintenance cost of the winning bidders, but also reduce the marketing cost of the non-bidding varieties, and realize the diminishing effect of marginal marketing costs
.
Taking Qilu Pharmaceutical as an example, as of December 9, 2021, the company has passed/deemed to pass the consistency evaluation of 93 varieties (174 product specifications), of which 40 are the first in China to pass the evaluation, including 33 injections that have passed the evaluation.
The number of varieties evaluated is leading
.
The enterprise has sufficient reserve over-evaluation varieties, which provides the advantage of product clustering for the market promotion of the bid-winning varieties
.
According to public information, among the first five batches of national procurement, Qilu Pharmaceutical won the bid for a total of 34 varieties, and the number came out on top
.
Especially for the fifth batch of national procurement, the price of Qilurivaroxaban (10mg) was reduced by 98%, the price of docetaxel was reduced by 94%, and the price of oxaliplatin injection was reduced by 89%.
This quotation strategy is a rational quotation in line with corporate >
.
In this batch of national harvests, Qilu has a total of 15 varieties listed.
Not surprisingly, the competition among these varieties will be more intense
.
The number of varieties evaluated is leading
.
The enterprise has sufficient reserve over-evaluation varieties, which provides the advantage of product clustering for the market promotion of the bid-winning varieties
.
According to public information, among the first five batches of national procurement, Qilu Pharmaceutical won the bid for a total of 34 varieties, and the number came out on top
.
Especially for the fifth batch of national procurement, the price of Qilurivaroxaban (10mg) was reduced by 98%, the price of docetaxel was reduced by 94%, and the price of oxaliplatin injection was reduced by 89%.
This quotation strategy is a rational quotation in line with corporate >
.
In this batch of national harvests, Qilu has a total of 15 varieties listed.
Not surprisingly, the competition among these varieties will be more intense
.
4.
Whether it is injection In general, oral dosage forms have a wide range of sales channels.
Even if the centralized procurement fails to win the bid, it can be sold outside the hospital by relying on the brand reputation
.
Injections are different.
If the centralized procurement fails to win the bid, it can basically be regarded as withdrawing from the domestic market.
Therefore, the competition of injection formulations is more intense.
There are 28 varieties of injections in this batch of national procurement
.
Whether it is injection In general, oral dosage forms have a wide range of sales channels.
Even if the centralized procurement fails to win the bid, it can be sold outside the hospital by relying on the brand reputation
.
Injections are different.
If the centralized procurement fails to win the bid, it can basically be regarded as withdrawing from the domestic market.
Therefore, the competition of injection formulations is more intense.
There are 28 varieties of injections in this batch of national procurement
.
Five competition levels
The intensity of competition among the 58 domestically harvested varieties in this batch can be divided into five levels:
One is the moderate level, with only 1 eliminated
.
This type of product is an original research drug company, all of which are oral preparations, and there is no bidding >
.
.
This type of product is an original research drug company, all of which are oral preparations, and there is no bidding >
.
The second is the game level, and only 1 player is eliminated
.
Such products are either oral preparations and no original research is involved, such as ornidazole, calcium acetate, isosorbide mononitrate, compound sulfamethoxazole, propranolol, cefixime, memantine hydrochloride, lacosamide, etc.
; Or it is an injection with the participation of the original researcher, and the number of competing products is 1+n, and the original research drug companies may compete for lower prices in the hospital market, such as methylprednisolone, micafungin, paricalcitol, temozolomide, octreotide , iopamidol, temozolomide
.
.
Such products are either oral preparations and no original research is involved, such as ornidazole, calcium acetate, isosorbide mononitrate, compound sulfamethoxazole, propranolol, cefixime, memantine hydrochloride, lacosamide, etc.
; Or it is an injection with the participation of the original researcher, and the number of competing products is 1+n, and the original research drug companies may compete for lower prices in the hospital market, such as methylprednisolone, micafungin, paricalcitol, temozolomide, octreotide , iopamidol, temozolomide
.
The third is the level of fierce competition, and there are strong bidders
.
Although one such product has been eliminated, there are aggressive companies with bidding >
.
Or oral preparations, reaching more than 6 reference standards, eliminating 2 companies, at least 1 is a local pharmaceutical company, such as erlotinib, flunarizine, lacosamide, mycophenolate mofetil, metoprolol Er
.
Or although 1 company is eliminated, there are aggressive companies with bidding >
.
.
Although one such product has been eliminated, there are aggressive companies with bidding >
.
Or oral preparations, reaching more than 6 reference standards, eliminating 2 companies, at least 1 is a local pharmaceutical company, such as erlotinib, flunarizine, lacosamide, mycophenolate mofetil, metoprolol Er
.
Or although 1 company is eliminated, there are aggressive companies with bidding >
.
The fourth is to be fully competitive, and 2 companies will be eliminated
.
The first type of product is injection, and there is no bidding >
.
The second is oral preparations, with aggressive bidding >
.
.
The first type of product is injection, and there is no bidding >
.
The second is oral preparations, with aggressive bidding >
.
The fifth is the "Red Sea" level, with more than 2 companies eliminated
.
The first is to eliminate more than two such products, such as omeprazole, clindamycin phosphate, tenofovir alafenamide, cefixime, and nifedipine sustained-release
.
Second, although 2 companies were eliminated, there were aggressive bidding->
.
.
The first is to eliminate more than two such products, such as omeprazole, clindamycin phosphate, tenofovir alafenamide, cefixime, and nifedipine sustained-release
.
Second, although 2 companies were eliminated, there were aggressive bidding->
.
On February 17, the Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Seventh Batch of State-Organized Centralized Drug Purchasing Relevant Drug Information Reporting Work".
This national procurement involves a total of 58 varieties and 208 product specifications
.
The "Notice" requires that starting from February 18, the seventh batch of drug information reporting work related to centralized drug procurement organized by the state will be carried out
.
Industry insiders predict that the quotation time for the seventh batch of national mining will be from March 25 to April 10
.
This national procurement involves a total of 58 varieties and 208 product specifications
.
The "Notice" requires that starting from February 18, the seventh batch of drug information reporting work related to centralized drug procurement organized by the state will be carried out
.
Industry insiders predict that the quotation time for the seventh batch of national mining will be from March 25 to April 10
.
Four influencing factors
At present, the seventh batch of national procurement is still in the stage of quantity quotation, and no corresponding bid-winning rules have been issued.
Based on the centralized procurement rules for the first five batches of chemical drugs and the winning bids, the author believes that the factors affecting this quotation are:
Based on the centralized procurement rules for the first five batches of chemical drugs and the winning bids, the author believes that the factors affecting this quotation are:
1.
The number of competing products From the results of the first five batches of winning bids, the number of competing products is positively correlated with the price drop, that is, the more the number of competing products, the greater the drop
.
According to the previous bidding rules, when there are more than 6 shortlisted companies, at least 2 companies must be eliminated, of which there must be 1 generic drug company, so the competition is fierce, and there are 33 varieties that meet this condition
.
The number of competing products From the results of the first five batches of winning bids, the number of competing products is positively correlated with the price drop, that is, the more the number of competing products, the greater the drop
.
According to the previous bidding rules, when there are more than 6 shortlisted companies, at least 2 companies must be eliminated, of which there must be 1 generic drug company, so the competition is fierce, and there are 33 varieties that meet this condition
.
2.
With or without the centralized procurement of the first five batches of chemical drugs from the original research, a total of 260 billion yuan of drug costs have been saved
.
At the national level, it is proposed to continue to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
Judging from the previous centralized procurement experience and the patent cliff situation in Europe and the United States, about 10% of the original research enterprises may win the bid, in other words, 90% of the original research enterprises can achieve imitation substitution
.
According to statistics, 43 of the 58 varieties involve original research enterprises
.
With or without the centralized procurement of the first five batches of chemical drugs from the original research, a total of 260 billion yuan of drug costs have been saved
.
At the national level, it is proposed to continue to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
Judging from the previous centralized procurement experience and the patent cliff situation in Europe and the United States, about 10% of the original research enterprises may win the bid, in other words, 90% of the original research enterprises can achieve imitation substitution
.
According to statistics, 43 of the 58 varieties involve original research enterprises
.
3.
The centralized procurement of domestic leading enterprises is conducive to the realization of the centralization of the domestic generic drug industry
.
Judging from the number of over-reviews, domestic generic drug varieties are more and more concentrated in leading companies, and the stronger will inevitably become stronger in the future
.
The top domestic pharmaceutical companies have a high probability of winning the bid.
The reasons are as follows: First, corporate strategy.
Most of the domestic leading pharmaceutical companies have implemented the strategy of combining imitation and innovation and competition in the industry chain, and have already deployed the first generic drugs and APIs to achieve a one-year market exclusivity period.
The second is the advantage of product clusters.
The increase in the number of bid-winning products will reduce the marketing cost of unit varieties
.
Most of the domestic leading pharmaceutical companies have many successful bidders, and the resulting brand advantage can not only reduce the maintenance cost of the winning bidders, but also reduce the marketing cost of the non-bidding varieties, and realize the diminishing effect of marginal marketing costs
.
The centralized procurement of domestic leading enterprises is conducive to the realization of the centralization of the domestic generic drug industry
.
Judging from the number of over-reviews, domestic generic drug varieties are more and more concentrated in leading companies, and the stronger will inevitably become stronger in the future
.
The top domestic pharmaceutical companies have a high probability of winning the bid.
The reasons are as follows: First, corporate strategy.
Most of the domestic leading pharmaceutical companies have implemented the strategy of combining imitation and innovation and competition in the industry chain, and have already deployed the first generic drugs and APIs to achieve a one-year market exclusivity period.
The second is the advantage of product clusters.
The increase in the number of bid-winning products will reduce the marketing cost of unit varieties
.
Most of the domestic leading pharmaceutical companies have many successful bidders, and the resulting brand advantage can not only reduce the maintenance cost of the winning bidders, but also reduce the marketing cost of the non-bidding varieties, and realize the diminishing effect of marginal marketing costs
.
Taking Qilu Pharmaceutical as an example, as of December 9, 2021, the company has passed/deemed to pass the consistency evaluation of 93 varieties (174 product specifications), of which 40 are the first in China to pass the evaluation, including 33 injections that have passed the evaluation.
The number of varieties evaluated is leading
.
The enterprise has sufficient reserve over-evaluation varieties, which provides the advantage of product clustering for the market promotion of the bid-winning varieties
.
According to public information, among the first five batches of national procurement, Qilu Pharmaceutical won the bid for a total of 34 varieties, and the number came out on top
.
Especially for the fifth batch of national procurement, the price of Qilurivaroxaban (10mg) was reduced by 98%, the price of docetaxel was reduced by 94%, and the price of oxaliplatin injection was reduced by 89%.
This quotation strategy is a rational quotation in line with corporate >
.
In this batch of national harvests, Qilu has a total of 15 varieties listed.
Not surprisingly, the competition among these varieties will be more intense
.
The number of varieties evaluated is leading
.
The enterprise has sufficient reserve over-evaluation varieties, which provides the advantage of product clustering for the market promotion of the bid-winning varieties
.
According to public information, among the first five batches of national procurement, Qilu Pharmaceutical won the bid for a total of 34 varieties, and the number came out on top
.
Especially for the fifth batch of national procurement, the price of Qilurivaroxaban (10mg) was reduced by 98%, the price of docetaxel was reduced by 94%, and the price of oxaliplatin injection was reduced by 89%.
This quotation strategy is a rational quotation in line with corporate >
.
In this batch of national harvests, Qilu has a total of 15 varieties listed.
Not surprisingly, the competition among these varieties will be more intense
.
4.
Whether it is injection In general, oral dosage forms have a wide range of sales channels.
Even if the centralized procurement fails to win the bid, it can be sold outside the hospital by relying on the brand reputation
.
Injections are different.
If the centralized procurement fails to win the bid, it can basically be regarded as withdrawing from the domestic market.
Therefore, the competition of injection formulations is more intense.
There are 28 varieties of injections in this batch of national procurement
.
Whether it is injection In general, oral dosage forms have a wide range of sales channels.
Even if the centralized procurement fails to win the bid, it can be sold outside the hospital by relying on the brand reputation
.
Injections are different.
If the centralized procurement fails to win the bid, it can basically be regarded as withdrawing from the domestic market.
Therefore, the competition of injection formulations is more intense.
There are 28 varieties of injections in this batch of national procurement
.
Five competition levels
The intensity of competition among the 58 domestically harvested varieties in this batch can be divided into five levels:
One is the moderate level, with only 1 eliminated
.
This type of product is an original research drug company, all of which are oral preparations, and there is no bidding >
.
.
This type of product is an original research drug company, all of which are oral preparations, and there is no bidding >
.
The second is the game level, and only 1 player is eliminated
.
Such products are either oral preparations and no original research is involved, such as ornidazole, calcium acetate, isosorbide mononitrate, compound sulfamethoxazole, propranolol, cefixime, memantine hydrochloride, lacosamide, etc.
; Or it is an injection with the participation of the original researcher, and the number of competing products is 1+n, and the original research drug companies may compete for lower prices in the hospital market, such as methylprednisolone, micafungin, paricalcitol, temozolomide, octreotide , iopamidol, temozolomide
.
.
Such products are either oral preparations and no original research is involved, such as ornidazole, calcium acetate, isosorbide mononitrate, compound sulfamethoxazole, propranolol, cefixime, memantine hydrochloride, lacosamide, etc.
; Or it is an injection with the participation of the original researcher, and the number of competing products is 1+n, and the original research drug companies may compete for lower prices in the hospital market, such as methylprednisolone, micafungin, paricalcitol, temozolomide, octreotide , iopamidol, temozolomide
.
The third is the level of fierce competition, and there are strong bidders
.
Although one such product has been eliminated, there are aggressive companies with bidding >
.
Or oral preparations, reaching more than 6 reference standards, eliminating 2 companies, at least 1 is a local pharmaceutical company, such as erlotinib, flunarizine, lacosamide, mycophenolate mofetil, metoprolol Er
.
Or although 1 company is eliminated, there are aggressive companies with bidding >
.
.
Although one such product has been eliminated, there are aggressive companies with bidding >
.
Or oral preparations, reaching more than 6 reference standards, eliminating 2 companies, at least 1 is a local pharmaceutical company, such as erlotinib, flunarizine, lacosamide, mycophenolate mofetil, metoprolol Er
.
Or although 1 company is eliminated, there are aggressive companies with bidding >
.
The fourth is to be fully competitive, and 2 companies will be eliminated
.
The first type of product is injection, and there is no bidding >
.
The second is oral preparations, with aggressive bidding >
.
.
The first type of product is injection, and there is no bidding >
.
The second is oral preparations, with aggressive bidding >
.
The fifth is the "Red Sea" level, with more than 2 companies eliminated
.
The first is to eliminate more than two such products, such as omeprazole, clindamycin phosphate, tenofovir alafenamide, cefixime, and nifedipine sustained-release
.
Second, although 2 companies were eliminated, there were aggressive bidding->
.
.
The first is to eliminate more than two such products, such as omeprazole, clindamycin phosphate, tenofovir alafenamide, cefixime, and nifedipine sustained-release
.
Second, although 2 companies were eliminated, there were aggressive bidding->
.
On February 17, the Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Carrying out the Seventh Batch of State-Organized Centralized Drug Purchasing Relevant Drug Information Reporting Work".
This national procurement involves a total of 58 varieties and 208 product specifications
.
The "Notice" requires that starting from February 18, the seventh batch of drug information reporting work related to centralized drug procurement organized by the state will be carried out
.
Industry insiders predict that the quotation time for the seventh batch of national mining will be from March 25 to April 10
.
This national procurement involves a total of 58 varieties and 208 product specifications
.
The "Notice" requires that starting from February 18, the seventh batch of drug information reporting work related to centralized drug procurement organized by the state will be carried out
.
Industry insiders predict that the quotation time for the seventh batch of national mining will be from March 25 to April 10
.
Four influencing factors
Four influencing factors At present, the seventh batch of national procurement is still in the stage of quantity quotation, and no corresponding bid-winning rules have been issued.
Based on the centralized procurement rules for the first five batches of chemical drugs and the winning bids, the author believes that the factors affecting this quotation are:
Based on the centralized procurement rules for the first five batches of chemical drugs and the winning bids, the author believes that the factors affecting this quotation are:
1.
The number of competing products From the results of the first five batches of winning bids, the number of competing products is positively correlated with the price drop, that is, the more the number of competing products, the greater the drop
.
According to the previous bidding rules, when there are more than 6 shortlisted companies, at least 2 companies must be eliminated, of which there must be 1 generic drug company, so the competition is fierce, and there are 33 varieties that meet this condition
.
The number of competing products From the results of the first five batches of winning bids, the number of competing products is positively correlated with the price drop, that is, the more the number of competing products, the greater the drop
.
According to the previous bidding rules, when there are more than 6 shortlisted companies, at least 2 companies must be eliminated, of which there must be 1 generic drug company, so the competition is fierce, and there are 33 varieties that meet this condition
.
2.
With or without the centralized procurement of the first five batches of chemical drugs from the original research, a total of 260 billion yuan of drug costs have been saved
.
At the national level, it is proposed to continue to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
Judging from the previous centralized procurement experience and the patent cliff situation in Europe and the United States, about 10% of the original research enterprises may win the bid, in other words, 90% of the original research enterprises can achieve imitation substitution
.
According to statistics, 43 of the 58 varieties involve original research enterprises
.
Purchasing , Purchasing , Purchasing , Medicine , Medicine , Pharmaceutical Enterprises , EnterprisesWith or without the centralized procurement of the first five batches of chemical drugs from the original research, a total of 260 billion yuan of drug costs have been saved
.
At the national level, it is proposed to continue to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
Judging from the previous centralized procurement experience and the patent cliff situation in Europe and the United States, about 10% of the original research enterprises may win the bid, in other words, 90% of the original research enterprises can achieve imitation substitution
.
According to statistics, 43 of the 58 varieties involve original research enterprises
.
3.
The centralized procurement of domestic leading enterprises is conducive to the realization of the centralization of the domestic generic drug industry
.
Judging from the number of over-reviews, domestic generic drug varieties are more and more concentrated in leading companies, and the stronger will inevitably become stronger in the future
.
The top domestic pharmaceutical companies have a high probability of winning the bid.
The reasons are as follows: First, corporate strategy.
Most of the domestic leading pharmaceutical companies have implemented the strategy of combining imitation and innovation and competition in the industry chain, and have already deployed the first generic drugs and APIs to achieve a one-year market exclusivity period.
The second is the advantage of product clusters.
The increase in the number of bid-winning products will reduce the marketing cost of unit varieties
.
Most of the domestic leading pharmaceutical companies have many successful bidders, and the resulting brand advantage can not only reduce the maintenance cost of the winning bidders, but also reduce the marketing cost of the non-bidding varieties, and realize the diminishing effect of marginal marketing costs
.
medicines medicines medicinesThe centralized procurement of domestic leading enterprises is conducive to the realization of the centralization of the domestic generic drug industry
.
Judging from the number of over-reviews, domestic generic drug varieties are more and more concentrated in leading companies, and the stronger will inevitably become stronger in the future
.
The top domestic pharmaceutical companies have a high probability of winning the bid.
The reasons are as follows: First, corporate strategy.
Most of the domestic leading pharmaceutical companies have implemented the strategy of combining imitation and innovation and competition in the industry chain, and have already deployed the first generic drugs and APIs to achieve a one-year market exclusivity period.
The second is the advantage of product clusters.
The increase in the number of bid-winning products will reduce the marketing cost of unit varieties
.
Most of the domestic leading pharmaceutical companies have many successful bidders, and the resulting brand advantage can not only reduce the maintenance cost of the winning bidders, but also reduce the marketing cost of the non-bidding varieties, and realize the diminishing effect of marginal marketing costs
.
Taking Qilu Pharmaceutical as an example, as of December 9, 2021, the company has passed/deemed to pass the consistency evaluation of 93 varieties (174 product specifications), of which 40 are the first in China to pass the evaluation, including 33 injections that have passed the evaluation.
The number of varieties evaluated is leading
.
The enterprise has sufficient reserve over-evaluation varieties, which provides the advantage of product clustering for the market promotion of the bid-winning varieties
.
According to public information, among the first five batches of national procurement, Qilu Pharmaceutical won the bid for a total of 34 varieties, and the number came out on top
.
Especially for the fifth batch of national procurement, the price of Qilurivaroxaban (10mg) was reduced by 98%, the price of docetaxel was reduced by 94%, and the price of oxaliplatin injection was reduced by 89%.
This quotation strategy is a rational quotation in line with corporate >
.
In this batch of national harvests, Qilu has a total of 15 varieties listed.
Not surprisingly, the competition among these varieties will be more intense
.
The number of varieties evaluated is leading
.
The enterprise has sufficient reserve over-evaluation varieties, which provides the advantage of product clustering for the market promotion of the bid-winning varieties
.
According to public information, among the first five batches of national procurement, Qilu Pharmaceutical won the bid for a total of 34 varieties, and the number came out on top
.
Especially for the fifth batch of national procurement, the price of Qilurivaroxaban (10mg) was reduced by 98%, the price of docetaxel was reduced by 94%, and the price of oxaliplatin injection was reduced by 89%.
This quotation strategy is a rational quotation in line with corporate >
.
In this batch of national harvests, Qilu has a total of 15 varieties listed.
Not surprisingly, the competition among these varieties will be more intense
.
4.
Whether it is injection In general, oral dosage forms have a wide range of sales channels.
Even if the centralized procurement fails to win the bid, it can be sold outside the hospital by relying on the brand reputation
.
Injections are different.
If the centralized procurement fails to win the bid, it can basically be regarded as withdrawing from the domestic market.
Therefore, the competition of injection formulations is more intense.
There are 28 varieties of injections in this batch of national procurement
.
Whether it is injection In general, oral dosage forms have a wide range of sales channels.
Even if the centralized procurement fails to win the bid, it can be sold outside the hospital by relying on the brand reputation
.
Injections are different.
If the centralized procurement fails to win the bid, it can basically be regarded as withdrawing from the domestic market.
Therefore, the competition of injection formulations is more intense.
There are 28 varieties of injections in this batch of national procurement
.
Five competition levels
Five competition levelsThe intensity of competition among the 58 domestically harvested varieties in this batch can be divided into five levels:
The intensity of competition among the 58 domestically harvested varieties in this batch can be divided into five levels: One is the moderate level, with only 1 eliminated
.
This type of product is an original research drug company, all of which are oral preparations, and there is no bidding >
.
.
This type of product is an original research drug company, all of which are oral preparations, and there is no bidding >
.
The second is the game level, and only 1 player is eliminated
.
Such products are either oral preparations and no original research is involved, such as ornidazole, calcium acetate, isosorbide mononitrate, compound sulfamethoxazole, propranolol, cefixime, memantine hydrochloride, lacosamide, etc.
; Or it is an injection with the participation of the original researcher, and the number of competing products is 1+n, and the original research drug companies may compete for lower prices in the hospital market, such as methylprednisolone, micafungin, paricalcitol, temozolomide, octreotide , iopamidol, temozolomide
.
.
Such products are either oral preparations and no original research is involved, such as ornidazole, calcium acetate, isosorbide mononitrate, compound sulfamethoxazole, propranolol, cefixime, memantine hydrochloride, lacosamide, etc.
; Or it is an injection with the participation of the original researcher, and the number of competing products is 1+n, and the original research drug companies may compete for lower prices in the hospital market, such as methylprednisolone, micafungin, paricalcitol, temozolomide, octreotide , iopamidol, temozolomide
.
The third is the level of fierce competition, and there are strong bidders
.
Although one such product has been eliminated, there are aggressive companies with bidding >
.
Or oral preparations, reaching more than 6 reference standards, eliminating 2 companies, at least 1 is a local pharmaceutical company, such as erlotinib, flunarizine, lacosamide, mycophenolate mofetil, metoprolol Er
.
Or although 1 company is eliminated, there are aggressive companies with bidding >
.
.
Although one such product has been eliminated, there are aggressive companies with bidding >
.
Or oral preparations, reaching more than 6 reference standards, eliminating 2 companies, at least 1 is a local pharmaceutical company, such as erlotinib, flunarizine, lacosamide, mycophenolate mofetil, metoprolol Er
.
Or although 1 company is eliminated, there are aggressive companies with bidding >
.
The fourth is to be fully competitive, and 2 companies will be eliminated
.
The first type of product is injection, and there is no bidding >
.
The second is oral preparations, with aggressive bidding >
.
.
The first type of product is injection, and there is no bidding >
.
The second is oral preparations, with aggressive bidding >
.
The fifth is the "Red Sea" level, with more than 2 companies eliminated
.
The first is to eliminate more than two such products, such as omeprazole, clindamycin phosphate, tenofovir alafenamide, cefixime, and nifedipine sustained-release
.
Second, although 2 companies were eliminated, there were aggressive bidding->
.
.
The first is to eliminate more than two such products, such as omeprazole, clindamycin phosphate, tenofovir alafenamide, cefixime, and nifedipine sustained-release
.
Second, although 2 companies were eliminated, there were aggressive bidding->
.
